Chanticleer
Why $3b Aussie darling Telix needs to grow wings
If Telix wants to truly mix it with the big players, it needs to be closer to those that can fund it.
Wall Street beckons for tearaway Australian biotech Telix Pharmaceuticals, one of the ASX’s best-performed companies over the past five years, and it is hard to see how the company’s board can resist.
The $3 billion Telix needs access to a bigger pool of biotech investors if it is to graduate from niche Aussie business success story to a serious global player that can compete with the big pharmaceutical companies coming for its patch.
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Healthcare & fitness
Fetching latest articles